Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America

Elena Quinonez, Majid Vahed, Abdolrazagh Hashemi Shahraki, View ORCID ProfileMehdi Mirsaeidi
doi: https://doi.org/10.1101/2021.03.30.21254648
Elena Quinonez
1Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Majid Vahed
2Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abdolrazagh Hashemi Shahraki
2Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehdi Mirsaeidi
2Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mehdi Mirsaeidi
  • For correspondence: msm249@med.miami.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction The outbreak of pneumonia known as SARS-COV-2 and newly-emerging South African (B.1.351), the United Kingdom (B.1.1.7) and Brazil (P.1) variants have led to a more infectious virus and potentially more substantial loss of neutralizing activity by natural infection or vaccine-elicited antibodies.

Methods We identified prevalent mutations using the spike receptor-binding domain (S-RBD) of SARS-CoV-2 deposited in the Nextstrain global database and comparing them to the Wuhan-Hu-1/2019 genomic sequence as a reference. Then we calculated the percentages of mutant genomes from the total regional subsample isolates from December 2019 to the end of January 2021. We developed two separate time series forecasting models for the SARS-CoV-2 B.1.1.7 variant. The computational model used the structure of the S-RBD to examine its interactions with the neutralizing antibody, named CV30 (isolated from a patient), and human angiotensin-converting enzyme 2 (hACE-2), based on a hybrid algorithm of template-based modeling to predict the affinity of S protein to the neutralizing antibodies and hACE-2 receptor.

Results The proportion of the B.1.1.7 strain in North America is growing fast. From these computations, it seems that the S-RBD and hACE-2 proteins are less favorable for the South African strain (K417N, E484K, and N501Y) as compared to the wild type structure and more favorable for B.1.1.7 and P.1 variants. In the present of crystallized CV30 neutralizing antibodies, docking scores suggest antibodies can be partially neutralize the B.1.1.7 variant, and, less efficiently, the B.1.351 and P.1 variants.

Conclusion The rapid evolution of SARS-CoV-2 has the potential to allow the newly-emerged B.1.351, and P.1 variants to escape from natural or vaccine-induced neutralizing immunity and viral spreading.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

None

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable. Nextstrain is an all-source code is freely available under the terms of the GNU Affero General Public License. Nextstrain is supported by NIH for research on pathogens including SARS-CoV2. We have accessed to de-identifiable data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: None

Data Availability

All data generated and analyzed during this study are included in this article [and its supplementary information files].

  • Abbreviations

    SARS-CoV1
    Severe acute respiratory syndrome coronavirus 1
    MERS-CoV
    Middle East respiratory syndrome coronavirus
    S-RBD
    Spike receptor-binding domain
    hACE-2
    Human angiotensin-converting enzyme 2
    U.S
    United State
    U.K
    United Kingdom
    COVID19
    Coronavirus disease 2019
    CDC
    Centers for Disease Control
    GISAID
    Global Initiative on Sharing All Influenza Data
    CSB PDB
    Protein Data Bank
    RMSD
    Root-mean-square deviation
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
    Back to top
    PreviousNext
    Posted March 31, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America
    Elena Quinonez, Majid Vahed, Abdolrazagh Hashemi Shahraki, Mehdi Mirsaeidi
    medRxiv 2021.03.30.21254648; doi: https://doi.org/10.1101/2021.03.30.21254648
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    A time series forecasting of the proportion of SARS-CoV-2 N501Y lineage in North America
    Elena Quinonez, Majid Vahed, Abdolrazagh Hashemi Shahraki, Mehdi Mirsaeidi
    medRxiv 2021.03.30.21254648; doi: https://doi.org/10.1101/2021.03.30.21254648

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (160)
    • Allergy and Immunology (412)
    • Anesthesia (90)
    • Cardiovascular Medicine (855)
    • Dentistry and Oral Medicine (157)
    • Dermatology (97)
    • Emergency Medicine (247)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
    • Epidemiology (8542)
    • Forensic Medicine (4)
    • Gastroenterology (383)
    • Genetic and Genomic Medicine (1741)
    • Geriatric Medicine (167)
    • Health Economics (371)
    • Health Informatics (1235)
    • Health Policy (618)
    • Health Systems and Quality Improvement (467)
    • Hematology (196)
    • HIV/AIDS (372)
    • Infectious Diseases (except HIV/AIDS) (10274)
    • Intensive Care and Critical Care Medicine (552)
    • Medical Education (192)
    • Medical Ethics (51)
    • Nephrology (210)
    • Neurology (1668)
    • Nursing (97)
    • Nutrition (248)
    • Obstetrics and Gynecology (325)
    • Occupational and Environmental Health (450)
    • Oncology (925)
    • Ophthalmology (263)
    • Orthopedics (100)
    • Otolaryngology (172)
    • Pain Medicine (111)
    • Palliative Medicine (40)
    • Pathology (252)
    • Pediatrics (534)
    • Pharmacology and Therapeutics (246)
    • Primary Care Research (207)
    • Psychiatry and Clinical Psychology (1760)
    • Public and Global Health (3831)
    • Radiology and Imaging (622)
    • Rehabilitation Medicine and Physical Therapy (318)
    • Respiratory Medicine (518)
    • Rheumatology (207)
    • Sexual and Reproductive Health (165)
    • Sports Medicine (157)
    • Surgery (190)
    • Toxicology (36)
    • Transplantation (100)
    • Urology (74)